SAN DIEGO—LeafBio Inc., the commercial arm of Mapp Biopharmaceutical Inc., has announced results from the Prevail II clinical trial of its ZMapp therapy for treatment of Ebola virus disease. The trial, conducted in Liberia, Sierra Leone, Guinea and the United States over the course of nearly a year, was initiated to evaluate the efficacy of ZMapp in treating Ebola, and concluded on Jan. 29, 2016. While the trial did not ultimately enroll enough patients to produce definitive results, researchers said the drug was well tolerated and showed promise. As a result, the U.S. Food and Drug Administration has encouraged Mapp Biopharmaceutical to continue to make ZMapp available to patients under an expanded access treatment protocol during the product’s ongoing development.